Φορτώνει......
Myositis and myasteniform syndrome related to pembrolizumab
This case report concerns a 63-year-old man affected by metastatic undifferentiated liposarcoma. After receiving pembrolizumab as a second-line treatment in a clinical trial, the patient experienced an immune-mediated myocarditis, myositis and myasteniform syndrome. The last two adverse events showe...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | BMJ Case Rep |
|---|---|
| Κύριοι συγγραφείς: | , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
BMJ Publishing Group
2021
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8296758/ https://ncbi.nlm.nih.gov/pubmed/34290006 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2021-241766 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|